Advertisement


Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease

IASLC World Conference on Lung Cancer

Advertisement

Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation ALK inhibitor, is superior to crizotinib in terms of progression-free survival as well as efficacy in central nervous system metastases for patients with ALK-positive non–small cell lung cancer (Abstract 2).



Related Videos

Lung Cancer
Immunotherapy

Paul Baas, MD, PhD, on Mesothelioma: First-Line Nivolumab Plus Ipilimumab vs Chemotherapy

Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses results of the CheckMate 743 trial, which suggests nivolumab plus ipilimumab should be considered the new s...

Lung Cancer

Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy

Misako Nagasaka, MD, of the Barbara Ann Karmanos Cancer Institute, discusses results of the ORIENT-11 trial, which showed that, although sintilimab ...

Lung Cancer
COVID-19

Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry

Marina C. Garassino, MD, of the Istituto Nazionale dei Tumori di Milano, discusses the global registry she and her colleagues created to track and a...

Advertisement

Advertisement



Advertisement